Recursion Director Blake Borgeson Sells 30,000 Shares

What Happened
Blake Borgeson, a director of Recursion Pharmaceuticals (RXRX), sold 30,000 shares on 2026-09-01 at $3.34 per share, generating proceeds of approximately $100,200. The sale is reported as an open-market/other sale (Code S) and was made pursuant to a pre-established Rule 10b5-1 trading plan.

Key Details

• Transaction date: 2026-09-01; Report filed: 2026-09-02 (timely filing).
• Price per share: $3.34; Shares sold: 30,000; Gross proceeds: ~$100,200.
• Sale executed under a Rule 10b5-1 trading plan adopted by the reporting person on August 31, 2025.
• Shares owned after the transaction: not specified in the provided filing details.
• Transaction type: Sale (Code S). No indication of option exercise, gift, or tax withholding in the reported transaction.

Context
Sales made pursuant to a 10b5-1 plan are typically pre-planned and do not necessarily reflect the insider’s current view of the company. For retail investors, purchases can be more informative about insider conviction; routine plan sales are common and often intended for diversification or liquidity.